News
Sensorion Publishes Results of Combined General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
DGAP-News: Abivax phase 2a study results of obefazimod (ABX464) in rheumatoid arthritis published in the journal “Annals of the Rheumatic Diseases” and selected for presentation at EULAR 2022
Poxel Announces its Participation in Upcoming Investor and Scientific Conferences
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Median Technologies Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials
Regulatory News:
Median Technologies (Paris:ALMDT) announces that the company is expanding its portfolio of services with Imaging Lab, a new entity whose mission is to leverage AI, data mining
Verimatrix nimmt an der BroadcastAsia und der Money 20/20 Europe teil
Verimatrix, (Paris:VMX) (Euronext Paris: VMX), der führende Anbieter von kundenorientierten Sicherheitslösungen für die moderne vernetzte Welt, kündigte heute seine Teilnahme an zwei
Eutelsat-Telenor Maritime Key Connectivity Maritime Deal Confirming the Central Role of Eutelsat ADVANCE Service in the Cruise Segment
Regulatory News:
Eutelsat Communications (Euronext Paris: ETL) (Paris:ETL) has been selected by Telenor Maritime for in-orbit resources and managed services for cruise connectivity on several of
Verimatrix To Participate in BroadcastAsia, Money 20/20 Europe
Regulatory News:
Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced it will participate in two
Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of PXT3003, the PREMIER Trial, for the Treatment of Charcot-Marie-Tooth Disease Type 1A
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting
Transgene’s Combined General Meeting of May 25, 2022
Regulatory News:
The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 25, 2022) at 10:00 a.m. at the Company’s headquarters (400
Alcineo setzt die Threat Defense-Technologie von Verimatrix zum Schutz von SoftPOS-Terminal-Lösungen für Banken und Zahlungsdienstleister ein
Verimatrix, (Paris:VMX) (Euronext Paris: VMX), der führende Anbieter von kundenorientierten Sicherheitslösungen für die moderne vernetzte Welt, gab heute bekannt, dass seine Lösung Verimatrix Code
Alcineo Deploys Verimatrix Threat Defense Technology To Protect SoftPOS Terminal Solutions for Banks, Payment Providers
Regulatory News:
Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced its Verimatrix Code Shield was
BALYO Signs a Commercial Agreement With Auchan for the Management of 2,000 Pallets Within Its "Fulfillment" Logistics Platform
Regulatory News:
BALYO (FR0013258399, Ticker: BALYO, eligible for PEA-PME savings schemes), a technological leader in the design and development of innovative robotic solutions for material
Vertragsabschluss zwischen BALYO und Auchan über das Management von 2 000 Paletten innerhalb seiner „Fulfillment“-Logistikplattform
BALYO (FR0013258399, Tickersymbol: BALYO, PEA-PME-qualifiziert), Technologieführer im Bereich Konzeption und Entwicklung innovativer Roboterlösungen für Flurförderzeuge, gibt den Abschluss eines
Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 14, 2022
Regulatory News:
The shareholders of Median Technologies (ALMDT:PA) are invited to participate at the Shareholders’ Ordinary and Extraordinary General Meeting which will be held on Tuesday June
RUBIS: Results from the capital increase reserved for Group employees
Nicox (COX): Eye health portfolio targets large markets
GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal
CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update
Regulatory News:
This replaces the announcement made at 4:40PM EDT/20:40 CEST on May 18 due to the following correction: Updated date in "First Quarter Operational Highlights" section.
NANOBIOTIX Provides First Quarter Operational and Financial Update
Regulatory News:
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for
DGAP-News: ABIVAX: Abivax announces annual ordinary and extraordinary general meeting on June 9, 2022, and the availability of the preparatory documents
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2022
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Transgene Announces Upcoming Investor Meetings
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that Management will
Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including